切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2013, Vol. 02 ›› Issue (01) : 45 -52. doi: 10.3877/cma.j.issn.2095-3232.2013.01.010

所属专题: 文献

基础研究

HSP70与PI3K/Akt信号通路在肝细胞肝癌组织中的表达及意义
刘金钢1,(), 李岩1, 刘丹1, 李航宇1   
  1. 1. 110004 沈阳,中国医科大学附属盛京医院普外科
  • 收稿日期:2012-11-02 出版日期:2013-02-10
  • 通信作者: 刘金钢
  • 基金资助:
    国家自然科学基金项目(81071955); 辽宁省教育厅科技项目(L2010634)

Expression and significance of HSP70 and PI3K pathway in hepatocellular carcinoma

Jin-gang LIU1,(), Yan LI1, Dan LIU1, Hang-yu LI1   

  1. 1. Department of Surgery, Sheng jing Hospital, China Meical University, Shenyang 110004, China
  • Received:2012-11-02 Published:2013-02-10
  • Corresponding author: Jin-gang LIU
  • About author:
    Corresponding author: LIU Jin-gang, Email:
引用本文:

刘金钢, 李岩, 刘丹, 李航宇. HSP70与PI3K/Akt信号通路在肝细胞肝癌组织中的表达及意义[J/OL]. 中华肝脏外科手术学电子杂志, 2013, 02(01): 45-52.

Jin-gang LIU, Yan LI, Dan LIU, Hang-yu LI. Expression and significance of HSP70 and PI3K pathway in hepatocellular carcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2013, 02(01): 45-52.

目的

探讨热休克蛋白(HSP)70、磷脂酰肌醇3-激酶(PI3K)和蛋白激酶B(Akt)在肝细胞肝癌(肝癌)组织中的表达及意义。

方法

本组回顾性研究标本来源于2005年3月至2008年12月在中国医科大学附属盛京医院接受诊治,经病理学诊断为肝癌的98例患者的手术切除标本。所有患者术前均签署知情同意书,符合医学伦理学规定。男69例,女29例,年龄31~70岁,中位年龄57岁。应用免疫组织化学方法检测HSP70、PI3K、Akt蛋白的特异性表达,用蛋白质印迹法检测肝癌组织中HSP70、PI3K、Akt蛋白的含量。应用实时逆转录-聚合酶链反应(real-time RT-PCR)检测HSP70、PI3K、Akt信使核糖核酸(mRNA)。观察肝癌组织中HSP70、PI3K、Akt蛋白和mRNA表达情况,分析其与患者性别、年龄、病理组织学分化、淋巴结转移和肿瘤、淋巴、转移(TNM)分期等临床病理学参数的关系。采用χ2检验和Fisher确切概率法比较HSP70、PI3K、Akt表达与临床病理学参数关系,采用单因素方差分析和LSD-t检验比较不同组织学分化程度的肝癌组织中HSP70、PI3K、Akt蛋白和mRNA含量差异,采用Pearson法分析HSP70、PI3K、Akt蛋白表达与组织学分化程度之间的关系,采用Kaplan-Meier法和Log-rank检验进行生存分析。

结果

98例患者中,HSP70蛋白阳性表达1级26例(27%),2级41例(42%),3级31例(32%);PI3K蛋白低表达和高表达分别为40例(41%)、58例(59%),Akt蛋白低表达和高表达分别为42例(43%)、56例(57%)。HSP70、PI3K、Akt蛋白表达与肝癌组织学分化程度有关(χ2=49.99、24.675、32.521,均为P<0.05),而与性别、年龄、淋巴结转移和TNM分期无关(均为P>0.05)。高、中、低分化肝癌组织中HSP70蛋白含量分别为0.5284±0.0056、0.8420±0.0260、0.9810±0.0020;PI3K蛋白含量分别为0.6047±0.0558、0.7027±0.0064、0.9311±0.0019;Akt蛋白含量分别为0.7139±0.0028、0.7756±0.0039、0.9701±0.0010,3组比较差异有统计学意义(F=75.546、76.007、69.693,均为P<0.05),低分化肝癌组织中HSP70、PI3K、Akt蛋白的含量明显高于高分化肝癌组织(t=12.256、11.560、10.532,均为P<0.05);HSP70、PI3K、Akt蛋白含量与肝癌组织学分化程度有关(r=0.387、0.715、0.713,均为P<0.01);以高分化肝癌组织中的mRNA相对表达量为1,中、低分化组的肝癌组织中HSP70 mRNA的相对表达量分别为1.674±0.008、2.234±0.006,PI3K分别为2.676±0.006、3.449±0.045,Akt分别为2.754±0.004、3.366±0.006,3组比较差异有统计学意义(F=9.784、16.580、5.933,P<0.05),低分化肝癌组织中HSP70、PI3K、Akt mRNA的相对表达量明显高于高分化的肝癌组织(t=0.126、0.8202、6.497,均为P<0.05);HSP70、PI3K和Akt mRNA的相对表达量与组织学分化程度有关(r=0.210、0.187、0.397,P=0.001、<0.01、<0.05)。HSP70蛋白的表达与PI3K和Akt蛋白(r=0.715、0.713,均为P=0.001)的表达呈正相关。HSP70蛋白表达为1级、2级和3级患者的术后平均无瘤生存时间分别为31、17和11个月,3组比较差异有统计学意义(均为P=0.001)。PI3K蛋白高表达和低表达患者术后平均无瘤生存时间分别为12、25个月,两组比较差异有统计学意义(P=0.003),Akt蛋白高表达和低表达的患者的术后平均无瘤生存时间分别为11、21个月,两组比较差异统计学意义(P=0.001)。

结论

肝癌组织中存在不同程度的HSP70、PI3K和Akt蛋白和mRNA表达,其表达与组织学分化程度有关;HSP70与PI3K/AKT信号传导通路之间可能具有协同促进肝癌细胞增殖的作用。肝癌组织中HSP70、PI3K和Akt蛋白表达是影响患者无瘤生存期的重要因素,HSP70蛋白表达量越高,患者预后越差。

Objective

To investigate the expression and clinical significance of heat shock protein (HSP) 70, phosphatidylinositol 3-kinase (PI3k) and protein kinase(Akt) in hepatocellular carcinoma(HCC).

Methods

A total of 98 patients diagnosed hepatocellular carcinoma pathologically were involved in this retrospective study. The patients underwent surgical resection at Shengjing Affiliated Hospital of China Medical University from March 2005 to December 2008. Local ethical committee approval was received and that the informed consent of all participating subjects was obtained. There were 69 males and 29 females with the age range of 31-70 years old and a median age of 57. Immunohistochemistry and Western blot were used to examine the expression and the level of HSP70, PI3K and Akt proteins respectively. Real-time reverse transcription polymerase chain reaction was used to examine the expression of HSP70, PI3K and Akt mRNA. The expression of HSP70, PI3k and Akt protein and mRNA was observed and the relationship between the gender, age, histological differentiation, lymph node metastasis, tumor-node-metastasis (TNM) staging were analyzed and compared by χ2 test and Fisher definite probability. The differences of HSP70, PI3K, Akt protein and mRNA content in HCC tissues of diverse differentiation were compared by one-way ANOVA analysis and LSD-t test and the correlation between them were analyzed using Pearson correlation analysis. Kaplan-Meier method and Log-rank test were used for survival analysis.

Results

Twenty-six(27%) cases presented HSP70 positive expression of grade 1, 41(42%) grade 2, and 31(32%) grade 3. The low expression of PI3K and Akt were observed in 40 (41%) and 42(43%) cases, and high expression in 58(59%) and 56 cases (57%) respectively. The expression of HSP70, PI3K, Akt protein were associated with HCC histological differentiation (χ2=49.99, 24.675, 32.521, all in P<0.05) , while were not related with the gender, age, lymph node metastasis, TNM staging (all in P>0.05) . The HSP70 protein levels of well, moderate, poorly differentiated HCC were 0.5284±0.0056, 0.8420±0.0260, 0.9810±0.0020; the PI3K protein content were 0.6047±0.0558, 0.7027±0.0064, 0.9311±0.0019; and the Akt protein levels were 0.7139±0.0028, 0.7756±0.0039, 0.9701±0.0010. There were significant differences between the three groups (F=75.546, 76.007, 69.693; all in P<0.05); The levels of HSP70, PI3K and of Akt protein expression in poorly differentiated HCC tissues were significantly higher than those in well differentiated HCC tissues (t=12.256, 11.560, 10.532; all in P<0.05); The HSP70, PI3K and Akt protein contents were associated with differentiation of HCC(r= 0.387, 0.715, 0.713; P<0.01); When the mRNA relative expression amount of HSP70, PI3K and Akt protein in well differentiated HCC was set as 1, the mRNA expression levels of HSP70 in moderate and poorly differentiated HCC were 1.674±0.008, 2.234±0.006, the PI3K were 2.676±0.006, 3.449±0.045, and the Akt were 2.754±0.004, 3.366±0.006 respectively. There were significant differences among the three groups(F=9.784, 16.580, 5.933; P<0.05). The HSP70, PI3K and of Akt mRNA expression amount in poorly differentiated HCC tissues were significantly higher than that in well differentiated ones (t=0.126, 0.8202, 6.497; P<0.05); The expression of HSP70, PI3K and Akt mRNA were associated with the differentiation grades of HCC (r=0.210, 0.187, 0.397; P=0.001, <0.01, <0.05); Expression of HSP70 was positively associated with the expression of PI3K and Akt protein (r=0.715, 0.713; all in P=0.001); The average tumour-free survival time of patients with HSP70 positive expression at grade 1, 2 and 3 were 31, 17 and 11 months respectively, which showed significant difference among 3 groups(P=0.001); The average tumour-free survival time of patients with high and low PI3K expression were 12 and 25 months, which showed significant difference between 2 groups(P=0.001); The average tumour-free survival time of patients with high and low Akt expression were 11 and 21 months, which also showed significant difference between the 2 groups(P=0.001).

Conclusions

The different expression of HSP70, PI3K, Akt and mRNA in HCC tissues are associated with histological differentiation. HSP70 and PI3K/AKT signaling pathway may have a synergistic role in promoting HCC cell proliferation. The expression of HSP70, PI3K and Akt protein in HCC tissues are important prognostic factors of patients’ tumor-free survival. The higher the HSP70 protein expression is, the worse prognosis the patients have.

图1 肝癌患者肿瘤组织中HSP70、PI3K和Akt蛋白的表达(SP法,×400)
表1 肝细胞肝癌组织中HSP70、PI3K、Akt蛋白表达与临床病理学参数的关系(例)
图2 Western blot法检测肝癌患者不同分化程度肿瘤组织中HSP70、PI3K和Akt的蛋白表达电泳图
图3 肝癌患者肿瘤组织中HSP70(a)、PI3K(b)及Akt(c)蛋白表达水平[以β-actin为参数(β-actin为β-肌动蛋白)]
图4 实时逆转录-聚合酶链反应检测肝癌患者肿瘤组织中HSP70、PI3K和Akt mRNA的扩增曲线
图5 不同组织学分化程度的肝癌肿瘤组织的HSP70、PI3K、Akt mRNA含量
[1]
Daugaard M, Rohde M, Jäättelä M. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett, 2007, 581(19):3702-3710.
[2]
Pierzchalski P, Krawiec A, Gawelko J, et al. Molecular mechanism of protection against chemically and gamma-radiation induced apoptosis in human colon cancer cells. J Physiol Pharmacol, 2008, 59(Suppl 2):191-202.
[3]
Cardoso F, Di Leo A, Larsimont D, et al. Evaluation of HER2, p53, bcl-2, topoisomerase Ⅱ-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol, 2001, 12(5):615-620.
[4]
Nylandsted J, Brand K, Jäättelä M. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci, 2000, 926:122-125.
[5]
Jung KH, Choi MJ, Hong S, et al. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway. Cancer Lett, 2012, 316(2):187-195.
[6]
Sobin LH, Gospondarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell, 2009: 73-77.
[7]
Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol, 2011, 7(10):1149-1167.
[8]
李航宇,孔凡民,董明,等. HSP70和JNK信号转导通路在肝癌组织中的表达及意义.中国组织化学与细胞化学杂志, 2006, 15(3):240-245.
[9]
Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation, 2002, 70(9/10):506-521.
[10]
Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res, 2012, 72(10):2473-2480.
[11]
Li H, Sui C, Kong F, et al. Expression of HSP70 and JNK-related proteins in human liver cancer: potential effects on clinical outcome. Dig Liver Dis, 2007, 39(7):663-670.
[12]
Hu W, Wu W, Yeung SC, et al. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Anticancer Res, 2002, 22(2A):665-672.
[13]
Prasad R, Vaid M, Katiyar SK. Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway. PLoS One, 2012, 7(8):e43064.
[14]
Sithanandam G, Smith GT, Masuda A, et al. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis, 2003, 24(10):1581-1592.
[15]
孙晓杰,黄常志. PI3K-Akt信号通路与肿瘤.世界华人消化杂志, 2006, 14(3):306-311.
[16]
Cheng JC, Chou CH, Kuo ML, et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene, 2006, 25(53):7009-7018.
[17]
Wang H, Liu H, Chen K, et al. SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep, 2012, 28(1):311-318.
[18]
Soond DR, Slack EC, Garden OA, et al. Does the PI3K pathway promote or antagonize regulatory T cell development and function? Front Immunol, 2012, DOI: 10.3389/fimmu.2012.00244[Epub ahead of print].
[19]
Namiecińska M, Marciniak K, Nowak JZ. VEGF as an angiogenic, neurotrophic, and neuroprotective factor. Postepy Hig Med Dosw (波兰文), 2005, 59:573-583.
[20]
Bruce D, Tan PH. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Cell Commun Adhes, 2011, 18(5):85-103.
[21]
Ping YF, Yao XH, Jiang JY, et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol, 2011, 224(3):344-354.
[22]
Yokoyama Y, Mori S, Hamada Y, et al. Platelet-derived growth factor regulates breast cancer progression via β-catenin expression. Pathobiology, 2011, 78(5):253-260.
[23]
Setia S, Sanyal SN. Downregulation of NF-κB and PCNA in the regulatory pathways of apoptosis by cyclooxygenase-2 inhibitors in experimental lung cancer. Mol Cell Biochem, 2012, 369(1/2):75-86.
[24]
Thiel A, Mrena J, Ristimäki A. Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev, 2011, 30(3/4):387-395.
[25]
Suzuki Y, Toquenaga Y. Effects of information and group structure on evolution of altruism: analysis of two-score model by covariance and contextual analyses. J Theor Biol, 2005, 232(2):191-201.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[8] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[9] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[10] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[11] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[12] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?